Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Clin Infect Dis. 2012 Nov 15;55(10):1291-8. doi: 10.1093/cid/cis714. Epub 2012 Aug 21.
The Republic of Congo has had no cases of wild poliovirus type 1 (WPV1) since 2000. In October 2010, a neurologist noted an abnormal number of cases of acute flaccid paralysis (AFP) among adults, which were later confirmed to be caused by WPV1.
Those presenting with AFP underwent clinical history, physical examination, and clinical specimen collection to determine if they had polio. AFP cases were classified as laboratory-confirmed, clinical, or nonpolio AFP. Epidemiologic features of the outbreak were analyzed.
From 19 September 2010 to 22 January 2011, 445 cases of WPV1 were reported in the Republic of Congo; 390 cases were from Pointe Noire. Overall, 331 cases were among adults; 378 cases were clinically confirmed, and 64 cases were laboratory confirmed. The case-fatality ratio (CFR) was 43%. Epidemiologic characteristics differed among polio cases reported in Pointe Noire and cases reported in the rest of the Republic of Congo, including age distribution and CFR. The outbreak stopped after multiple vaccination rounds with oral poliovirus vaccine, which targeted the entire population.
This outbreak underscores the need to maintain high vaccination coverage to prevent outbreaks, the need to maintain timely high-quality surveillance to rapidly identify and respond to any potential cases before an outbreak escalates, and the need to perform ongoing risk assessments of immunity gaps in polio-free countries.
刚果共和国自 2000 年以来再无野生 1 型脊灰病毒(WPV1)病例。2010 年 10 月,一位神经科医生注意到成人急性弛缓性麻痹(AFP)病例异常增多,后经证实这些病例是由 WPV1 引起的。
出现 AFP 的患者接受临床病史、体格检查和临床标本采集,以确定是否患有脊灰。将 AFP 病例分为实验室确诊、临床确诊和非脊灰 AFP。分析了疫情的流行病学特征。
2010 年 9 月 19 日至 2011 年 1 月 22 日,刚果共和国共报告 445 例 WPV1 病例;其中 390 例来自黑角。总体而言,331 例发生在成人中;378 例为临床确诊,64 例为实验室确诊。病死率(CFR)为 43%。在黑角报告的脊灰病例和共和国其他地区报告的脊灰病例之间,流行特征存在差异,包括年龄分布和 CFR。经过多轮针对所有人的口服脊灰疫苗接种后,疫情得到控制。
此次疫情凸显了以下需求:维持高疫苗接种覆盖率以预防疫情、维持及时的高质量监测,以便在疫情升级之前迅速发现和应对任何潜在病例、并对无脊灰国家的免疫空白进行持续风险评估。